EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Minimal Component, Protein‐Free, and Cost‐effective Human Pluripotent Stem Cell Cardiomyocyte Differentiation

Jessika B Iwanski, Odunayo S Lawal, William T Kwon, Isabella Vazquez, Jared M Churko iD

Current Protocols · 2025

DOI: 10.1002/cpz1.70099 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Protocols, 2025. Verfasst von Jessika B Iwanski und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular and Molecular Medicine, The University of Arizona, Tucson, Arizona. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Cell Differentiation, Pluripotent Stem Cells, Cell Culture Techniques. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American Heart Association, NHLBI NIH HHS, Center for Innovation in Brain Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human pluripotent stem cell‐derived cardiomyocytes (hPSC‐CMs) have become a powerful source for the in vitro modeling of cardiac diseases and various other essential applications, including cardiotoxicity screening and regenerative cell replacement therapies. Although many differentiation protocols have been developed to generate cardiomyocytes from human pluripotent stem cells, these protocols are costly and complex, requiring expensive and often unnecessary components (e.g., B27 medium supplement). In addition, the use of animal‐derived growth factors limits their use for regenerative medicine purposes. To address these issues, herein, we have developed an efficient, cost‐effective, and protein‐free hPSC‐CM protocol using only two components: DMEM/F12 basal medium and l ‐ascorbic acid 2‐phosphate. By eliminating xenobiotic and complex components, the efficiency of directed differentiations is increased, the variability between cardiac differentiations is decreased, and the scalability of cell production is enhanced. Adaptation of this efficient, low‐cost, and user‐friendly cardiac differentiation protocol will enrich the utility and applicability of hPSC‐CMs in drug discovery, cell therapies, tissue engineering, disease modeling, precision medicine, and cardiac regenerative medicine. © 2025 The Author(s). Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1 : hPSC cell culture Basic Protocol 2 : hPSC‐CM differentiation Basic Protocol 3 : Characterization of hPSC‐CMs by immunofluorescence (IF) imaging

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocytes, CardiacCell DifferentiationPluripotent Stem CellsCell Culture TechniquesHumansCost-Benefit AnalysisCulture Media

Stichwörter der Autor:innen

animal‐freecardiomyocyteshPSC‐CMprotein‐freestem cells

Substanzen

Culture Media

Autor:innen und Institutionen

  • Department of Cellular and Molecular Medicine, The University of Arizona, Tucson, Arizona.
  • Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas.
  • These authors contributed equally to this work.
  • Department of Clinical Translational Sciences, The University of Arizona, Tucson, Arizona.
  • BIO5 Institute, The University of Arizona, Tucson, Arizona.

ORCID-Profile: Jared M Churko

Förderung

  • American Heart Association
  • NHLBI NIH HHS
  • Center for Innovation in Brain Science
  • Gootter-Jensen Foundation
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Iwanski, J. B., Lawal, O. S., Kwon, W. T., Vazquez, I., & Churko, J. M. (2025). Minimal Component, Protein‐Free, and Cost‐effective Human Pluripotent Stem Cell Cardiomyocyte Differentiation. Current Protocols. https://doi.org/10.1002/cpz1.70099

Vancouver

Iwanski JB, Lawal OS, Kwon WT, Vazquez I, Churko JM. Minimal Component, Protein‐Free, and Cost‐effective Human Pluripotent Stem Cell Cardiomyocyte Differentiation. Current Protocols. 2025. doi:10.1002/cpz1.70099

BibTeX
@article{Iwanski2025,
  author = {Iwanski, Jessika B and Lawal, Odunayo S and Kwon, William T and Vazquez, Isabella and Churko, Jared M},
  title = {Minimal Component, Protein‐Free, and Cost‐effective Human Pluripotent Stem Cell Cardiomyocyte Differentiation},
  journal = {Current Protocols},
  year = {2025},
  doi = {10.1002/cpz1.70099}
}
Kostenlos starten →